-

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time.

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclusion of the live broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Karen Possemato
media@veracyte.com

Industry:

Veracyte, Inc.

NASDAQ:VCYT
Release Versions
English

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Karen Possemato
media@veracyte.com

More News From Veracyte, Inc.

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference – London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference – Nashville, TN Fireside Chat on November 20t...

Veracyte Announces Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Veracyte’s chief executive officer. “We continue to advance our mission of transforming cancer care by generat...

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool’s ability to help define the future of thyroid nodule evaluation. Using the company’s innovative whole-transcriptome-derived research-use-only platform, researchers analyzed molecular data from thyroid nodules to develop signatures with potential...
Back to Newsroom